Palleon announces IND clearance for first-in-class cancer immunotherapy

Phase 1/2 trial of E-602 expected to open in Q1 2022 in patients with solid tumours

Immune Biosolutions lead immunotherapy product neutralises Covid-19

In addition to its favourable activity profile, IBIO123 is formulated for administration by inhalation providing an efficient, rapid and non-invasive delivery method into the lungs via the respiratory tract

Novartis collaborates with BeiGene to strengthen immunotherapy pipeline

Innovative market development collaboration also signed, expanding the availability of select Novartis oncology products in regions across China currently not covered by Novartis

Chiba University study flags allergy risk in high-binding antibody drugs

For the biopharma industry, the study strengthens the case for balancing immune-cell engagement with tolerability in antibody discovery platforms

ImmunityBio responds to FDA concerns over promotional content

AstraZeneca combo therapy shows breakthrough in liver cancer trial

The study met its primary endpoint, showing a statistically significant and clinically meaningful improvement in progression-free survival

Merck secures landmark EU nod for KEYTRUDA in hard-to-treat ovarian cancer

Its a major breakthrough for women’s ovarian cancer care in Europe

Agenus launches landmark global Phase 3 trial in hard-to-treat colorectal cancer

The study targets patients with refractory, unresectable microsatellite-stable (MSS)/mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC)

ImmunityBio scores first Asian approval for ANKTIVA in Macau

The Macau authorization followed a regulatory review that considered prior decisions by both the US FDA) and the European Medicines Agency

Bristol Myers Squibb scores major win with new Opdivo nods for Hodgkin Lymphoma in US, EU

These approvals represent a defining moment for people living with classical Hodgkin Lymphoma